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Clinically Significant Drug Interactions Associated
with Highly Active Antiretroviral Therapy
John J. Faragon*, PharmD, Assistant Professor of Pharmacy Practice, Albany College of Pharmacy
Clinical Pharmacist, Albany Medical College
Peter J. Piliero**, M.D., Associate Professor of Medicine, Albany Medical College, Clinical Consultant, New
York State Department of Corrections

One of the most challenging issues facing
providers treating patients with human immunodeficiency virus - 1 (HIV) infection is the complex
problem of drug interactions associated with highly active antiretroviral therapy (HAART).
Guidelines for the initial treatment of HIV infection
recommend the use of at least three antiretroviral
medications, each of which is associated with significant drug interactions.1 Further increasing the
risk of drug interactions is the concurrent treatment of co-morbid disease states and therapies
for prevention and/or treatment of opportunistic
infections (OIs). This review focuses on the clinically significant drug interaction associated with
the use of HAART.

Drug Interaction Overview
Currently, there are 21 medications from four different classes licensed in the United States for the
treatment of HIV infection. Drug interactions
associated with HIV medications can be broadly
classified into those that alter pharmacokinetics
and those that alter pharmacodynamics. 2
Pharmacokinetic drug interactions generally result
in a change in pharmacokinetic parameters, such
as the area under the curve (AUC), which is a
common measure of drug exposure, peak concentration (Cmax), trough concentration, or halflife. Conversely, pharmacodynamic interactions
result in alterations in the pharmacologic activity of
the medication; generally not causing a change in
pharmacokinetic parameters. The vast majority of
drug interactions encountered in HIV medicine are
pharmacokinetic in nature and occur as a result of
a change in the absorption, distribution,
metabolism or elimination of either the HIV
medication itself or the concurrently administered
medication.3
The cytochrome P450 (CYP450) enzyme system
is responsible for the biotransformation of drugs
from active to inactive metabolites that are readily
excreted by the body. Given the effects of the protease inhibitor (PI) and non-nucleoside reverse
transcriptase (NNRTI) class on the CYP450 system, metabolism drug interactions are most com-
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mon and problematic when prescribing HAART.
Though numerous isoenzymes of CYP450 have
been identified, the enzymes responsible for the
elimination of the majority of drugs used in HAART
are CYP3A4, CYP1A2, and CYP2D6. Table 1
describes the route of elimination for HAART.

Nucleoside/nucleotide reverse
transcriptase inhibitors
Drug interactions associated with the nucleoside
(NRTI) and nucleotide (NtRTI) classes are minimal, as these medications are not metabolized by
the CYP450 system. However, drug interactions
may still occur within this class.
The currently available NRTIs and NtRTI include
zidovudine, didanosine, zalcitabine, stavudine,
lamivudine, abacavir, emtricitabine, and tenofovir.
Drug interactions with zidovudine are minimal;
however, one of the few pharmacodynamic interactions encountered in HIV medicine occurs with
co-administered zidovudine and stavudine. Since
both of these NRTIs are thymidine analogues,
they can compete for the same phosphorylation
site in the growing chain of HIV DNA, resulting in
an antagonistic, pharmacodynamic interaction.3
These two agents should therefore never be combined.
The use of didanosine (ddI) is often complicated
by drug interactions. The buffered tablet formulation, which contains magnesium and calcium to
improve systemic absorption, interacts with certain antibiotics.4 As a result of the buffer chelating
the antibiotic, reduced ciprofloxacin, tetracycline
or doxycycline absorption may occur. To minimize
this interaction, ddI should be administered at
Continued on page 2
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Clinically Significant Drug
Interactions...(continued from page 1)
least two hours after or six hours before the
fluoroquinolone. 5 Concurrent use of ddIbuffered tablet may also impair the absorption
of the protease inhibitor (PI) atazanavir, since
atazanavir requires an acidic environment for
absorption. 6 Patients should take a ddIbuffered tablet two hours after or one hour
before taking atazanavir to minimize the interaction. Alternatively, use of the enteric-coated
capsule formulation is an option; however,
providers need to be sure that patients separate ddI and atazanavir since their dietary
restrictions differ.6,7
Probably the most significant ddI drug interaction reported occurs when didanosine is
used concurrently with the NtRTI tenofovir.
When enteric-coated ddI is co-administered
with tenofovir, the ddI AUC increases by
60%.8 As a result, the recommendation for
patients weighing >60kg who receive these
medications concurrently is to reduce the ddI
dosage to 250mg once daily. For patients
weighing <60kg, no specific guidelines are
available for ddI dosing; however, reduction
to 200mg once daily is likely warranted. For
severely underweight patients, providers may
consider an even further ddI dosage reduction to 125mg once daily. Due to the magnitude of this interaction, all patients receiving
concurrent tenofovir and ddI should be monitored closely for ddI-related toxicities such as
pancreatitis, hyperlactatemia, and lactic acidosis, regardless of ddI dosage adjustments.

Non Nucleoside Reverse
Transcriptase Inhibitors
Three NNRTIs are currently licensed for use
in the US: nevirapine, delavirdine, and
efavirenz. Drugs in this class are prone to
drug interactions, given the fact that they are
extensively metabolized via CYP3A4 and can
act as either inducers or inhibitors of
CYP3A4. Nevirapine and efavirenz are, in
general, inducers of CYP3A4, while delavirdine is an inhibitor of CYP3A4. When one of
these agents is combined with a medication
that is also metabolized by CYP3A4, a drug
interaction is likely to occur.
Numerous drug interactions with nevirapine
have been identified. Nevirapine is a CYP3A4
inducer, therefore most drug interactions
associated with it lead to an increase in
metabolism and reduced concentration of the
co-administered drug. For example, when
nevirapine is given concurrently with
methadone, withdrawal symptoms may occur
as a result of reduced methadone levels.9-12
When using methadone and nevirapine concurrently, patients should be monitored closely for signs and symptoms of methadone
withdrawal. Since the full effects of CYP3A4
induction may take time, signs of withdrawal
may occur one to two weeks (or longer) after

2

visit HEPP Report online at www.hivcorrections.org
TABLE 1: Routes of Elimination of Antiretroviral Agents and the
Effect on CYP450
Drug
Zidovudine
(AZT, ZDV)
Didanosine (ddI)
Zalcitabine (ddC)
Stavudine (d4T)
Lamivudine (3TC)
Tenofovir (TDF)
Abacavir (ABC)
Emtricitabine (FTC)
Nevirapine (NVP)
Delavirdine (DLV)
Efavirenz (EFV)
Saquinavir (SQV)
Ritonavir (RTV)

Elimination
Hepatic metabolism with
renal excretion
Renal excretion 50%
Renal excretion 70%
Renal excretion 50%
Renal excretion 70%
Renal excretion 70-80%
Hepatic
Renal excretion 86%
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic

Indinavir (IDV)
Nelfinavir (NFV)
Amprenavir (APV)
Lopinavir/ritonavir
(LPV/rtv)

Hepatic
Hepatic
Hepatic
Hepatic

Ataznavir (ATZ)

Hepatic

Fosamprenavir (FPV)
Enfuvirtide (ENF)

Hepatic
Hepatic

Effect on CYP450 System
None
None
None
None
None
None
Insignificant
None
CYP3A4 inducer
CYP3A4 inhibitor
CYP3A4 inducer/inhibitor
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP2D6 inhibitor
(3A4 inhibition >2D6)
3A4 and CYP1A2 inducer
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP2D6 inhibitor
(3A4 inhibition >2D6)
3A4 and CYP1A2 inducer
CYP3A4 inhibitor, CYP1A2,
CYP2C9 inhibitor
CYP3A4 inhibitor
None

Adapted from Reference 21.

nevirapine is added to methadone. An
increase in methadone dosage may be necessary after the addition of nevirapine.
Concurrent nevirapine and oral contraceptive
use may lead to contraceptive failure; therefore providers should recommend alternate
methods of birth control.13 Rifabutin and
rifampin are also potent CYP3A4 inducers
and have been shown to reduce nevirapine
trough concentrations by 16% and 37%,
respectively. Therefore, patients on nevirapine who require anti-mycobacterial therapy
should be given rifabutin to minimize the
reduction in nevirapine drug levels.
Efavirenz is a potent inducer of CYP3A4 in
vivo. As with nevirapine, CYP3A4 induction
properties of efavirenz can result in reduced
concentrations of concurrently administered
drugs that are also metabolized by CYP3A4.
In vitro data also suggest that efavirenz can
inhibit CYP3A4. Efavirenz is therefore contraindicated with midazolam, triazolam, and
ergotamine derivatives since there is a potential for increased drug concentrations of these
medications and associated toxicity. 14
Despite the inclusion of these contraindicated
medications in the product labeling, no published case reports to date have either proven

or refuted the validity of these interactions.
Concurrent use of the macrolide antibiotic
clarithromycin should be avoided in patients
receiving concurrent efavirenz. When used
together, the clarithromycin AUC and Cmax
decreased by 39% and 26%, respectively.14
Therefore, clinicians may consider using
azithromycin instead, as CYP450 drug interactions are unlikely with this medication.
Similar to nevirapine, methadone withdrawal
has also been reported with concurrent use of
efavirenz and methadone. This is more likely
to occur when adding efavirenz to a stable
methadone regimen.12 Providers should be
aware that the full effect of methadone withdrawal may take one to two weeks. Any
change to antiretroviral therapy (ART) regimens should be communicated to methadone
maintenance providers so that potential drug
interactions may be anticipated and avoided.
Concurrent use of efavirenz with rifampin has
been shown to reduce the AUC and Cmax of
efavirenz by 26% and 20%, respectively.
Although the clinical significance of this interaction is unknown, providers should increase
the efavirenz dosage to 800mg daily to offset
this interaction when using rifampin to treat
Continued on page 4
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Letter from the Editor
Dear Colleagues:
Currently, there are twenty-one medications that have been FDA approved for the treatment
of HIV infection. Most HIV-infected persons who have access to treatment are experiencing
highly active antiretroviral therapy- (HAART) associated immune reconstitution, are less
likely to develop an opportunistic infection or malignancy, and are living longer.
However, as we wade with our patients into this ever-growing pool of medications, the risks
associated with polypharmacy have increased exponentially. Drug-drug interactions have
been recognized that can lead to life-threatening toxicities or subtherapeutic medication levels. Clinicians who are not knowledgeable about these potential interactions can unwittingly contribute to the development of resistant strains of HIV. Alternatively, uninformed choices can lead to the failure of opportunistic infection prophylaxis or treatment.
The onus is therefore upon us as HIV care providers to be aware of the myriad of potential
adverse interactions that accompany the medications in our armamentarium. In addition, we
must be cognizant of interactions that may occur with over-the-counter drugs, herbal remedies, and recreational drugs. This month's lead article by Dr. John Faragon of Albany
College of Pharmacy and Dr. Peter Piliero of Albany Medical College provides a thorough
review of the clinically significant drug interactions associated with HAART. This month's
HIV 101 addresses drug interactions that can occur with the concurrent use HAART and
methadone.
Next month we will bring you an update on Tuberculosis and a Spotlight on the growing role
of electronic medical records in the management of chronic diseases, with a focus on products that are currently being used in the correctional setting.
As always, we welcome your feedback and suggestions. We value the collaborative relationship that we have developed with you, our readers and colleagues in correctional health
care. It is our sincere hope that HEPP Report's first issue of 2004 meets your expectations,
and that we continue to serve as a useful resource to you throughout the coming year.
Sincerely,
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TABLE 2: Dosing Recommendations when Combining Non Nucleoside
Reverse Transcriptase Inhibitors and Protease Inhibitors

tuberculosis.15 Another alternative would be
to use rifabutin instead of rifampin; current
guidelines suggest that the rifabutin dose be
increased to 450 mg daily and the dosage of
efavirenz should remain at 600mg once daily.

Protease Inhibitor/Non Nucleoside
Reverse Transcriptase Inhibitor
Combination
Indinavir with efavirenz or nevirapine

Unlike efavirenz and nevirapine, delavirdine is
a potent inhibitor of CYP3A4. As a result, concurrent administration of drugs metabolized
by the same isoenzyme are likely to cause
increased drug levels and potential drug toxicity. Drugs that are likely to have increased
serum levels when used concurrently with
delavirdine include alprazolam, midazolam,
triazolam, sildenafil, ergot alkaloid derivatives, nifedipine, and the HMGCoA-reductase
inhibitors simvastatin and lovastatin. 16
Concurrent use of these medications should
be avoided in patients receiving delavirdine.

Indinavir with delavirdine

The medications rifampin and rifabutin have
also been shown to reduce the AUC of
delavirdine by 96% and 80%, respectively.
Current guidelines for ART recommend that
these medications be avoided in patients
receiving concurrent delavirdine due to the
high risk for development of resistance and
virologic failure.15,16
Other potential drug interactions with the
entire NNRTI class include the anticonvulsants phenytoin, carbamazepine, and phenobarbital. Since these medications induce the
CYP450 system, reduced drug levels of
delavirdine, efavirenz, and nevirapine may
occur and should be avoided if possible. A
potential alternative is the medication levetiracetam and may be considered with concurrent ARV treatment, as it does not have
significant CYP450 interactions. When prescribing levetiracetam, the patient should
have close follow-up with a neurologist.
In treating patients who have failed their first
regimen, or are in deeper salvage therapy,
providers may be forced to use NNRTIs and
PIs together. Providers need to be cognizant
of dosage changes required when using
these two classes concurrently, given the
effect of both classes on the CYP3A4 system.
As the NNRTIs efavirenz and nevirapine are
known inducers of the CYP3A4 system, significant reductions in PI levels may occur
when using these drugs concurrently. For
example, when using efavirenz or nevirapine
with indinavir or lopinavir/ritonavir, the AUC of
the PIs are reduced by about 33%. To offset
this interaction, providers need to increase
the PI dosage: for indinavir the dosage needs
to be increased to 1000mg every eight hours,
and for lopinavir/ritonavir, the dosage needs
to be increased to four capsules
(533mg/133mg) twice daily.17,18 Conversely,
as delavirdine is a potent inhibitor of CYP3A4,

4

Amprenavir with efavirenz or nevirapine
Lopinavir/ritonavir with efavirenz or
nevirapine
Atazanavir with efavirenz (and probably nevirapine, though dosages have
not been established with nevirapine)
Fosamprenavir with efavirenz (and
probably nevirapine, though dosages
have not been established with nevirapine)

Dosage recommendation

Standard dose for efavirenz and nevirapine.
Increase indinavir dosage to 1000mg every
eight hours.
Standard dose delavirdine. Decrease indinavir dosage to 600mg every eight hours.
Standard dose for efavirenz and nevirapine.
Increase amprenavir dosage to 1200mg
three times daily.
Standard dose for efavirenz and nevirapine.
Increase lopinavir/ritonavir dose to
533mg/133mg (four capsules) twice daily.
Standard dose for efavirenz and probably
nevirapine.Give atazanavir 300mg once
daily AND add ritonavir 100mg once daily
Standard dose for efavirenz and probably
nevirapine. If using fosamprenavir with ritonavir twice daily, give fosamprenavir 700mg
with ritonavir 100mg twice daily. If using fosamprenavir with ritonavir once daily, give
fosamprenavir 1400mg with ritonavir 300mg
once daily.

Data from references 17-21.

concurrent use with indinavir requires a
dosage reduction to 600 mg every eight
hours.17 No data exist that describe the
pharmacokinetic
interaction
between
lopinavir/ritonavir and delavirdine.
Concurrent use of the two new PIs atazanavir
and fosamprenavir with either efavirenz or
nevirapine also result in reduction in PI levels.
However, instead of dosage adjustments,
data suggest that the addition of ritonavir to
these PIs is a viable option to offset the reductions in PI drug level. For example, during
concurrent use of atazanavir and efavirenz,
atazanavir AUC was reduced by about 74%.19
To offset the interaction, providers need to
reduce the atazanavir dosage to 300mg once
daily and also add ritonavir 100mg once daily.
When boosted fosamprenavir once daily is
used concurrently with efavirenz, fosamprenavir should be given 1400mg with 300mg of
ritonavir once daily or fosamprenavir 700mg
with ritonavir 100mg both twice daily. 20
Though data evaluating the drug interaction
between nevirapine and either atazanavir or
fosamprenavir are unavailable, expert opinion
suggests that the same dosage adjustments
should be made, given the similarity in
efavirenaz and nevirapine metabolism. Data
combining these medications with delavirdine
is not available. See Table 2 for a summary of
dosage recommendations with select PI and
NNRTI combinations.

Protease Inhibitors
All PIs are potent inhibitors of CYP3A4, and
as a result, drug interactions are often very

complex. As a result of CYP3A4 inhibition,
medication levels of agents also metabolized
by the same izoenzyme have the potential to
be markedly increased by the PI, potentially
leading to an increased incidence of adverse
effects. PIs have differing affinities for the
CYP3A4 isoenzyme. The most potent
inhibitor of CYP3A4 is ritonavir, whereas the
least potent is saquinavir; CYP3A4 inhibition
associated with indinavir, nelfinavir, and
amprenavir, and atazanavir tends to be intermediate.21 Ritonavir is often the most likely
medication in the PI class to cause drug interactions because in addition to its CYP3A4
inhibition, it also inhibits CYP2D6 and induces
CYP1A2 and CYP2C9. However, ritonavir is
often used to enhance the pharmacokinetic
parameters of co-administered PIs due to its
potent inhibition of their metabolism by
CYP3A4.
Numerous medications should be avoided
when using PI-based therapy. The benzodiazapines midazolam and triazolam are contraindicated, as these medications are metabolized by CYP3A4 and their concentrations
can be markedly increased, resulting in prolonged sedation. Though the benzodiazapine
alprazolam may also be increased by concurrent PI therapy, low doses may be acceptable
to use. Other potential alternatives to these
agents include lorazepam, oxazepam, or
temazepam, as these medications are not
metabolized by CYP450.21
Hyperlipidemia is a common occurrence with
Continued on page 5
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Clinically Significant Drug
Interactions...(continued from page 4)
PI therapy, though it may also be associated
with stavudine and efavirenz. As a result,
providers often treat hyperlipidemia with
either fibric acid derivatives or with HMG-CoA
reductase inhibitors, also referred to as
statins. Although drug interactions with the
fibric acid derivatives have not been identified, the use of certain statins is contraindicated with the use of a PI. The two most problematic statins are simvastatin and lovastatin,
as these agents are extensively metabolized
via CYP3A4.22 When used concurrently with
PIs, these statin levels are markedly
increased, placing the patient at risk for
myopathy, rhabdomyolysis, and possibly
renal failure and death. Statins that are considered safe include pravastatin or fluvastatin,
as they have minimal effect on CYP450,
therefore reducing the risk of drug interactions. Another potential option is atorvastatin,
however CYP3A4 is involved with its metabolism. Use of atorvastatin with PI therapy
should be done only with the lowest available
dosages and with close follow-up for potential
hepatotoxicity and muscle toxicity. The
newest statin, rosuvastatin, cannot be recommended as no drug interaction studies exist
evaluating concurrent PI use.
The use of PIs (and NNRTIs) often complicates the treatment of mycobacterial infections such as tuberculosis and MAC because
rifampin and rifabutin are potent inducers of
CYP3A4, leading to significant reductions in
PI levels. However, rifampin is much more
problematic, as it is a more potent inducer of
CYP3A4 compared to rifabutin. Therefore,
concurrent use of rifampin with PI regimens
that do not include ritonavir is generally contraindicated due to risks of subtherapeutic levels of PIs that can result in either virologic failure or resistance.
Herbal therapy is common in the setting of
HIV infection.23 Oftentimes, herbal therapies
have not been studied with concurrent
HAART, and therefore their use should be discouraged unless data evaluating their effect
on HAART are available. St. John's wort and
garlic supplementation significantly reduce
the levels of the PIs indinavir and saquinavir
soft gel capsule, respectively.24,25 Since other
PIs and NNRTIs are also metabolized by
CYP3A4, similar interactions with other medications in these classes would be expected.
Therefore, patients should be encouraged to
avoid St. John's wort, garlic supplements, and
other herbal therapies that have not been formally studied with PIs. The herbal therapy
milk thistle, often used as a hepatoprotectant,
has been shown to have minimal effects on
the PI indinavir.26 Providers choosing to offer
milk thistle to patients may be able to do so
safely with PI- and NNRTI-based therapies;

visit HEPP Report online at www.hivcorrections.org
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TABLE 3: Drugs to Avoid With PI-Based HAART Regimens
Drug
Ergot alkaloids such
as dihydroergotamine, ergonovine,
ergotamine,
methylergonovine
Simvastatin, lovastatin, high dose
atorvastatin

Interaction
Impaired hepatic metabolism
from PI reported to increase
risk of ergotamine toxicity

Recommendation
Avoid concurrent use with
PI therapy. Consider alternative drugs such as
sumatriptan.

HMG CoA reductase inhibitor
levels markedly increased

Phenytoin,
carbamazepine,
phenobarbital

Potential for increased metabolism of PI, leading to virologic
failure

Alprazolam,
midazolam, triazolam

Potential for prolonged or
increased sedation or respiratory depression
Cisapride

Select pravastatin or low
dose atorvastatin during
concurrent PI therapy as
alternatives.
Avoid concurrent use if
possible. Consider alternative anticonvulsant during
PI therapy.
Avoid concurrent use.
Consider zolpidem or
lorazepam.
Contraindicated due to
marked increase in cisapride levels and potential
for QT prolongation
Avoid concurrent use during PI therapy.

GI motility agents

St. John's wort

Garlic

Pimozide

Rifampin

Amiodarone,
propafenone, bepridil,
quinidine, flecainide
Proton Pump
Inhibitors such as
omeprazole,
esomeprazole, lansoprazole, rabeprazole,
pantoprazole

Significant decrease in PI (IDV
studied) levels, potentially leading to virologic failure or resistance
Significant decrease in PI
(SQV studied) levels, potentially leading to virologic failure or
resistance
Potential increased risk of cardiac toxicity with concurrent
ritonavir use
Significant decrease in PI concentrations, potentially leading
to virologic failure
May use with full dose ritonavir
Potential increased risk for
severe cardiac arrhythmias
with concurrent ritonavir use
Significant reductions in
atazanavir plasma concentrations

Avoid concurrent use with
PI therapy.

Avoid concurrent use with
ritonavir-based regimens,
including lopinavir/ritonavir.
Consider rifabutin as an
alternative.

Avoid concurrent use with
ritonavir-based regimens,
including lopinavir/ritonavir.
Avoid concurrent use with
atazanavir; consider use of
an H2 receptor antagonist
separated by at least 12
hours from atazanavir
administration.

Adapted from reference 19, 21

however, data demonstrating its effect on PIs
exist only for indinavir.
Drugs for erectile dysfunction, such as sildenafil, vardenafil and the recently approved
tadalafil, can also have their levels increased
significantly by concurrent PI use.27-29
Specifically, sildenafil levels can be increased
from two to eleven-fold when used concurrently with PI therapy. Therefore, clinicians
should prescribe, at most, 25mg every 48
hours initially. For patients who do not
respond to 25mg, consideration for using
higher doses should only be done with
extreme caution. PIs can also increase vardenafil concentrations.

Current guidelines from the product labeling
suggest that for patients on a PI-based regimen that does not include ritonavir, the maximum initial dose of vardenafil should be
2.5mg, without repeating the dose for 24
hours.29 For patients receiving ritonavir even
at low doses, the maximum initial vardenafil
dose should be 2.5mg and should not be
repeated for 72 hours.29 Tadalafil was also
recently approved; maximum doses used
should not exceed 10mg every 72 hours for
patients receiving concurrent PI therapy.30
Possible toxicities from these drugs include
priapism, hypotension, and visual color
changes.
Continued on page 6
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Clinically Significant Drug
Interactions...(continued from page 5)
HIV-infected patients may either have a
seizure disorder or may require seizure prophylaxis due to OIs that involve the central
nervous system. This often becomes problematic in the setting of HAART due to very
limited data on concurrent use of anticonvulsants and PIs. Use of the anticonvulsants
phenytoin, phenobarbital, and carbamazepine is of particular concern as they
induce CYP450 enzymes that may lead to
reduced PI or NNRTI levels.21 In fact, one
case report in the literature describes ART
failure possibly related to carbamazepine
therapy in a patient receiving a PI.31 In this
case, 200 mg of carbamazepine was taken
with 800 mg of indinavir every eight hours,
which led to subsequent virologic failure.
Therefore, concurrent use of these drugs with
PIs should be avoided, and a different anticonvulsant should be considered. More
recently, a drug interaction study was reported between lopinavir/ritonavir and phenytoin.32 When used together, a dual interaction
occurred, such that the levels of both lopinavir
and phenytoin were markedly reduced.
Therefore, providers should avoid this combination and select an alternative HAART regimen or an alternative anticonvulsant. One
potential option is the use of levetiracetam, an
anticonvulsant that has minimal drug interactions. Use of this medication in HIV-infected
patients has not been studied, and therefore
its use for treatment or prevention of seizures
should only be done with close consultation
with a neurologist. Whenever possible,
patients who require concurrent HAART and
anticonvulsant therapy should undergo periodic monitoring of anticonvulsant drug levels.
For some PIs, therapeutic drug monitoring
may also be an option to ensure that adequate levels are being attained. Consensus
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trough concentrations have been established
and are available in the most recent revision
of the federal Department of Health and
Human Services Guidelines.1
Patients infected with HIV-1 may require antifungal therapy for such infections as cryptococcal meningitis, or candidiasis. With regard
to PI drug interactions, the safest of the oral
medications is fluconazole, as drug interactions are minimal.33,34 However, the azole
antifungal ketoconazole is a potent CYP3A4
inhibitor and increases the level of drug exposure to saquinavir and amprenavir by 190%
and 31%, respectively.35,36 Conversely, ritonavir and lopinavir/ritonavir have demonstrated
a three-fold increase in ketoconazole levels
when used concurrently. Therefore doses
>200 mg/day of ketoconazole are not recommended when using these medications concurrently.18 In general, ketoconazole should
be avoided with concurrent HAART. The
newest azole antifungal, voriconazole, has
significant activity against aspergillosis and
candida albicans. Its use for treatment of candidiasis in HIV-infected patients has been
established; however, drug interaction data
only exist for concurrent use of indinavir,
where no clinically significant interaction
occurred.37 Although extrapolation to other
PIs may be possible, until data are available,
use of this azole with other PI-containing regimens (especially those that contain ritonavir)
should be undertaken when an alternative
azole cannot be used, and with close monitoring for voriconazole toxicity, such as elevated transaminases and visual toxicity.
One of the recently approved PIs for use in
the U.S. is atazanavir.19 Drug interactions with
atazanavir are very similar to the other PIs;
however, some differences do exist. In particular, atazanavir is a pH-dependent medication, requiring an acidic environment for
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absorption. As a result, the use of drugs that
may alter the gastric pH are likely to be problematic. Since antacids may reduce
atazanavir absorption, atazanavir should be
administered two hours before or one hour
after antacids. Proton pump inhibitors (PPIs)
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daily histamine-2 (H-2) receptor antagonist
separated by 12 hours from atazanavir. The
current thought is that H2 blockers provide
less prolonged suppression of acid, and, if
separated, the interaction should be minimized. However, no data exist to prove or
refute this theory.19
Other significant drug interactions may also
occur with concurrent PI use. Table 3 summarizes medications that should generally be
avoided with concurrent PI therapy.

Conclusions
Drug interactions are often complex and may
be difficult to predict due to limited studies.
Providers should be diligent in educating
themselves about routes of metabolism for
HAART and commonly prescribed medications to help recognize potential medications
that may be problematic. As therapy for HIV
changes very rapidly, providers may utilize
internet resources to help screen for potential
drug interactions and to identify new treatment options and issues surrounding HIV
infection (See Resources on p.8). With such
interventions, toxicity or adverse events
associated with drug interactions may be
prevented.
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Drug Interactions with HAART and Methadone
EFFECT OF ANTIRETROVIRAL
THERAPY ON METHADONE
NUCLEOSIDE/NUCLEOTIDE ANALOGUES
Decreased methadone clearance 25%
Abacavir
Unknown
Didanosine, buffered tablet
Unknown
Didanosine, entericcoated capsule
Lamivudine
Unknown
DRUG

Stavudine
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Unknown
Unknown
Unknown
Unknown

NON NUCLEOSIDE ANALOGUES
Delavirdine
Unknown, although potential increased
methadone effect
Decreased methadone levels 57%
Efavirenz
Decreased methadone levels 51%
Nevirapine
PROTEASE INHIBITORS (PIS)
Decreased methadone AUC 35%
Amprenavir
No significant change in methadone AUC
Indinavir

Lopinavir-ritonavir
Nelfinavir

Decreased methadone AUC 36%
Decreased methadone AUC 40%

Ritonavir
Saquinavir, hard-gel capsule
Saquinavir, soft-gel capsule

Decreased methadone AUC 36%
Unknown with saquinavir as sole PI
Unknown with saquinavir as sole PI;
unbound methadone concentrations
unchanged when using saquinavir and
ritonavir concurrently

EFFECT OF METHADONE ON
ANTIRETROVIRAL THERAPY
Decreased abacavir peak concentration 34%
Decreased didanosine AUC 57%
No significant change in didanosine AUC
No significant change when given as
zidovudine-lamivudine
Decreased stavudine AUC 23%
No significant change in tenofovir DF
Unknown
Increased zidovudine AUC 41%
No change in delavirdine or N-delavirdine
Unknown
Unknown
Decreased amprenavir AUC, Cmax, Cmin
Insignificant change in indinavir AUC;
increased indinavir Cmin 50%-100%;
decreased indinavir Cmax 16%-36%
Unknown
Decreased nelfinavir metabolite (M8) AUC
53%; clinical significance unknown
Unknown
Unknown with saquinavir as sole PI
Unknown with saquinavir as sole PI; potential
reduction in saquinavir Cmin when using
saquinavir and ritonavir concurrently

AUC, area under the concentration time curve; Cmax, maximum drug concentration or peak level; Cmin, minimum drug concentration or trough level.
Drug Interactions Associated With HAART: Focus on Treatments for Addiction and Recreational Drugs. AIDS Reader 13(9):433-450, 2003. Available at
www.medscape.com/viewarticle/461892_4
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Save the
Dates
Using Enfuvirtide (T20)
in Clinical Care
January 15, 2004
Boston, Massachusetts
Seminar topics will include:
Antiretroviral Drugs; Drug
Resistance; HIV/AIDS
Treatment or Therapies
Sponsored by The New England
AIDS Education and Training
Center (NEAETC).
Call: 617.262-5657
Visit: www.neaetc.org
The 11th Conference
on Retroviruses and
Opportunistic Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org
8th North American Region
Conference of the International
Union Against Tuberculosis
and Lung Disease
February 26-28, 2003
Austin, Texas
Themes will include Global
Threats to Regional TB;
Cross-Border TB Issues;
Treatment Strategies and
Disparities of TB Control in LowIncident Countries; and
Scientific Challenges for
TB Control: Resistance,
Drug Discovery, and
Laboratory Methods.
Call: 312.243.2000; Fax:
312.243.3954; TB@alamc.org;
www.lungchicago.org or
www.iuatld.org.
Management of HIV/AIDS in
the Correctional Setting:
A Live Satellite
Videoconference Series
Albany Medical Center
March 16, 2004
12:30 PM - 3:30 PM EST
CME and Nursing credits available
Call: 518.262.4674
Email: ybarraj@mail.amc.edu
To register as a site in your area
visit www.amc.edu/Patient/hiv/
hivconf/index.htm.
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Inside News
Rise in Syphilis Among MSM in San
Francisco Linked to Internet
The internet is a major factor in San Francisco's
increase in early syphilis infections among men
who have sex with men (MSM), according to a
recent study from the CDC. A focus on data for
415 MSM diagnosed with early syphilis in 2002
found that internet chat rooms were the most
common venues for meeting partners. Last year,
the city reported the highest rates of first and second-stage syphilis of any metropolitan area in the
nation. Between 1998-2002, early syphilis cases
increased from 41 to 495. Officials noted at the
time the proportion of cases among MSM had
jumped from 22 percent in 1998 to 88 percent in
2002. However, the CDC and San Francisco
Department of Public Health officials say that
they have evidence that internet-based partner
notification can be an effective tool for finding and
treating early syphilis infections.
"Internet Use and Early Syphilis Infection Among
Men Who Have Sex with Men - San Francisco,
California, 1999-2003," MMWR
(2003;52(50):1229-1232).
Bioequivalence study: 500 mg pill of Invirase
Two 200 mg formulations of Saquinavir (SQV)
are currently marketed for oral administration in
the treatment of HIV infection: Invirase, a hard
gelatin capsule (saquinavir mesylate) and
Fortovase, a soft gelatin capsule (saquinavir
base). Both formulations have shown good efficacy and safety when boosted with ritonavir (r) in
a SQV/r dosing of 1000/100 mg bid. The pill
count for a SQV/r regimen using the current 200
mg formulation is 12 pills per day. Roche is developing a 500 mg saquinavir mesylate tablet that is
smaller than the existing 200 mg formulation,
allowing the use of only two SQV tablets twice
daily in combination with ritonavir. The lower pill
count and improved convenience may improve
adherence to SQV/r regimens.
Boffito, Marta et al 9th EACS, October 2003,
Warsaw, Poland. Oral Abstract
Study: Safety, Tolerability, and Efficacy of
Interferon/Ribavirin Combination Therapy in
Methadone Maintenance (MM) Patients with
Active Hepatitis C (HCV)
In this study from the University of California, 78
percent of MM treated patients completed the six
to 12 month course of interferon/ribavirin combination therapy. The end-of-treatment virologic

response rate was 64% in patients completing
treatment and 54% in an intent-to-treat analysis.
Despite the fact that MM patients exhibit a number of factors that make HCV treatment challenging, such as older age, a higher prevalence of
psychiatric illness, and more advanced liver disease, their end-of-treatment response rate to
therapy is similar to that of patients without a history of IDU. These preliminary suggest that that
MM patients should be considered as potential
candidates for HCV treatment.
Sylvestre, DL. Treating Hepatitis C in
Methadone Maintenance Patients: An Interim
Analysis, Drug and Alcohol Dependence 67 (2)
(2002) pp. 117 - 123.
Study: Gilead Announces Preliminary
Results from 48-Week Phase III Study of
Emtricitabine in Patients with Chronic
Hepatitis B
Preliminary results from a Phase III clinical trial
comparing the efficacy and safety of emtricitabine
200 mg once daily versus placebo in patients with
chronic hepatitis B have been released. The
results demonstrate improvements in liver histology in 62% of patients who received the drug
compared to 25% of patients who received placebo (p less than 0.001). Improvement in liver histology was the primary endpoint in this study.
Gilead expects to present these data in detail at
a scientific conference next year.
www.natap.org 11/26/03
New CDC HIV Prevention Funding
Emphasizes Effectiveness, Focuses on
Those Already Infected
The federal Centers for Disease Control and
Prevention (CDC) has announced $49 million in
HIV prevention grants that require grantees to
prove that their efforts are effective and focus
more on doing prevention among people who are
already infected with the virus. "The announcement included some specific items that are called
program performance indicators," said Dr. Harold
W. Jaffe, director of CDC's National Center for
HIV, STD and TB Prevention. "They attempt to
set goals." The CDC expects to fund roughly 160
grants ranging in amounts from $100,000 to
$500,000, according to the December 3, 2003
announcement. The grants will run for five years,
but the $49 million represents only the first year's
funding.
HIV Update, 12/15/03

Resources
www.hiv.medscape.com
New data from conferences, CE articles on HIV
related topics and more.
www.aidsinfo.nih.gov
DHHS Guidelines for treatment of HIV infected
adults, adolescents, children...
www.hivandhepatitis.com
Treatment/developments for Hepatits A, B and C

and conferences/new journal articles related to
HIV/AIDS.
www.hopkins-aids.edu
HIV clinical trials/developments and animation of
viral life cycle that includes action of ART
www.hivguidelines.org
NYSDOH AIDS Institute Clinical Guidelines for
adults, pediatrics, ART in adults, and more.
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2004.
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The following two antiretroviral agents compete for the same
phosphorylation site in the growing chain of HIV DNA, resulting in
an antagonistic, pharmacodynamic interaction:
(a) zidovudine and stavudine
(b) zidovudine and didanosine
(c) didanosine and stavudine
(d) lamivudine and emtricitabine
2. The following antiretroviral agent contains magnesium and calcium and therefore interferes with the absorption of antibiotics such
as ciprofloxacin, tetracycline and doxycycline.
(a) zidovudine
(b) didanosine
(c) abacavir
(d) tenofovir
3. Which of the following statements is true:
(a) Nevirapine and efavirenz are, in general, inhibitors of
CYP3A4, while delavirdine is an inducer of CYP3A4
(b) when nevirapine is given concurrently with methadone,
intoxication symptoms may occur as a result of increased
methadone levels
(c) When enteric-coated ddI is co-administered with tenofovir,
the ddI AUC increases 60%.
(d) Abacavir increases the metabolism of oral contraceptives
and can lead to contraceptive failure; therefore providers
should recommend alternate methods of birth control for
patients receiving abacavir.

Statins which are considered safe because of minimal cytochrome
P450 interactions include:
(a) lovastatin and atorvastatin
(b) simvastatin and lovastatin
(c) pravastatin and fluvastatin
(d) lovastatin and pravastatin
6. When rifampin must be used for treatment of a mycobacterial
infection, the following is an appropriate concurrent dose:
(a) Nelfinavir 1250 mg p.o. bid
(b) Indinavir 800 mg p.o. tid
(c) Saquinivir 1200 mg p.o. bid
(d) Efavirenz 800 mg p.o. qd

HEPP Report Evaluation
5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor
1. Please evaluate the following sections with respect to:
Main Article
Inside News
Save the
Dates

educational value
5 4 3 2 1
5 4 3 2 1

clarity
5 4 3 2 1
5 4 3 2 1

5 4 3 2 1

5 4 3 2 1

2. Do you feel that HEPP Report helps you in your work?
Why or why not?

4. When used together with one of the following antiretrovirals, the
AUC and Cmax of clarithromycin decreased 39% and 26%,
respectively. Concurrent use of clarithromycin should therefore be
avoided in patients receiving:
(a) nelfinavir
(b) efavirenz
(c) lopinavir
(d) abacavir

3. What future topics should HEPP Report address?

5. The concentrations of some "statins" are markedly increased by
concurrent protease inhibitor therapy, placing the patient at risk for
myopathy, rhabdomyolysis, and possibly renal failure and death.

5. Do you have specific comments on this issue?

4. How can HEPP Report be made more useful to you?
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